| To: rkrw who wrote (212) | 3/3/2008 6:41:50 PM | | From: sammaster | | | | thanks for reply...
thats only about a 5% increase in 4 months...
flml just came out with earnings today...
only about 2 million in royalties from coreg cr(high margin) and maybe about 3 million fromm manufacturing coreg cr(low margin)..
guess coreg will provide the cash flow so they dont have to raise cash, but not quite the cash cow that a lot of people were expecting...
10 medusa contracts is great but they will take years to get to market...
maybe if flml gets a final washout selling it will be worth it to put away for a few years in a long term portfolio... |
| | Avadel AVDL | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Arthur Radley | 9/1/2009 4:39:35 PM | | | | | | | Stock pulled back today in overall down market........but with new 52 week high last week they seem to be moving under the radar. They continue to build cash with growing deals, so maybe it's time to revisit this old time favorite. |
| | Avadel AVDL | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: Arthur Radley | 9/22/2009 10:45:22 AM | | | | | | cc.talkpoint.com
Would suggest all listen to the UBS presentation this morning. The project announced for the funding being done by the French government is important..........listen to Willard's explanation, plus the 'promised' two new projects this Q and next Q.
One has to appreciate Willard's constant reminder of the 'shareholders' in the company plans. Sort of novel to have a CEO being concerned about the investors. (:>) |
| | Avadel AVDL | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Arthur Radley who wrote (218) | 11/4/2009 8:47:38 AM | | From: Arthur Radley | | | | Flamel Technologies Announces Licensing Agreement with Pfizer
8:00 am ET 11/04/2009 - Business Wire
LYON, France--(BUSINESS WIRE)--
Flamel Technologies (Nasdaq:FLML) today announced that Pfizer (NYSE:PFE)
has exercised its option to license Flamel's Medusa(R) technology for the
development of a controlled release formulation of an already-marketed
therapeutic protein. Flamel will receive a further payment of $1 million
pursuant to the exercise of the license; Pfizer will pay all development
costs of the program, including milestone payments and royalties on any
worldwide commercial sales. The program was begun in 2007 with Wyeth,
which was acquired by Pfizer last month. The program leverages Flamel's
ability to create controlled-release formulations of therapeutic
proteins for intravenous administration.
Stephen H. Willard, Flamel's chief executive officer, commented,
"Pfizer's decision to move forward follows a two year evaluation period
during which Flamel has developed and demonstrated an aspect of the
Medusa platform which allows us to work on controlled release
formulations of molecules that are injected intravenously. We believe
that this work has the potential to benefit patients in many ways, not
least by lessening the time and costs associated with frequent hospital
visits." |
| | Avadel AVDL | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Arthur Radley who wrote (219) | 11/4/2009 1:31:17 PM | | From: Arthur Radley | | | | | Q report is now on schedule for Friday of this week. The key will be whether they can continue to build their cash position. From the 1Q to the 2Q they increased cash from $39.1 million to $45.0 Million, so with several previously announced deals being booked during the 3rdQ it will be important to see if they can continue to keep cost down and build their cash reserves. Stock has bounced with PFE deal announcement today, but volume is only average........so appears new money coming in will be keyed to Q report. |
| | Avadel AVDL | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
